and evaluations of a synthetic pyrano[3,2-c]quinoline derivative as a potent anti-diabetic agent.

Background: The assessment of a novel compound is a pivotal step in the development of a new drug. In this study, we selected 1-(2-bromophenyl)-1,11-dihydro-3H-benzo[h]pyrano[3,2-c]quinoline-3,12(2H)-dione (), identified as an exemplary α-glucosidase inhibitor in preliminary in vitro assays, for further evaluation in an anti-diabetic context.

Methods: The anti-diabetic effect of was assessed using a streptozotocin (STZ)-induced diabetic Wistar rat model. Recognizing the relevance of lipid factors in diabetes, we also investigated the impact of this compound on the lipid profile of diabetic Wistar rats. studies, encompassing docking studies and pharmacokinetic predictions of 2-BDBPQD, were conducted.

Results: The results obtained indicated a significant reduction in blood glucose levels with treatment compared to acarbose. However, no significant effects on the lipid profile were observed. studies revealed that interacted with key residues in the α-glucosidase active site and exhibited favorable pharmacokinetic properties.

Conclusion: In summary, the study demonstrated the anti-hyperglycemic activity of . Nevertheless, further evaluations are recommended to comprehensively assess its potential as a new drug for the treatment of diabetes.